Corcept Therapeutics (NASDAQ:CORT) Insider Sells $418,544.00 in Stock

Posted by George Bondi on Aug 9th, 2026

Corcept Therapeutics Incorporated (NASDAQ:CORT – Get Free Report) insider William Guyer sold 3,700 shares of Corcept Therapeutics stock in a transaction dated Tuesday, August 4th. The shares were sold at an average price of $113.12, for a total transaction of $418,544.00. Following the transaction, the insider directly owned 3,985 shares of the company’s stock, valued at $450,783.20. This represents a 48.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

William Guyer also recently made the following trade(s):

On Tuesday, July 7th, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $93.13, for a total transaction of $1,862,600.00.
On Tuesday, June 2nd, William Guyer sold 20,000 shares of Corcept Therapeutics stock. The stock was sold at an average price of $70.60, for a total transaction of $1,412,000.00.

Corcept Therapeutics Trading Up 2.6%

NASDAQ:CORT opened at $110.77 on Friday. The stock has a market capitalization of $11.97 billion, a P/E ratio of 263.74 and a beta of 0.45. Corcept Therapeutics Incorporated has a 1 year low of $28.66 and a 1 year high of $122.21. The firm has a 50 day moving average of $89.31 and a 200-day moving average of $59.37.

Corcept Therapeutics (NASDAQ:CORT – Get Free Report) last released its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The firm had revenue of $256.15 million during the quarter, compared to analysts’ expectations of $221.15 million. During the same period last year, the firm posted $0.29 EPS. The business’s revenue was up 31.7% on a year-over-year basis. As a group, analysts forecast that Corcept Therapeutics Incorporated will post 1.13 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. UBS Group set a $135.00 price target on Corcept Therapeutics in a report on Thursday, May 28th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a research report on Monday, July 27th. Zacks Research upgraded shares of Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, May 4th. Canaccord Genuity Group increased their price target on shares of Corcept Therapeutics from $135.00 to $150.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Piper Sandler reissued an “overweight” rating and issued a $165.00 price target (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $119.17.

Check Out Our Latest Stock Report on CORT

Institutional Trading of Corcept Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of CORT. BlackRock Inc. bought a new position in Corcept Therapeutics during the 2nd quarter worth approximately $1,080,964,000. Parallel Advisors LLC increased its stake in Corcept Therapeutics by 2.5% in the first quarter. Parallel Advisors LLC now owns 3,977,404 shares of the biotechnology company’s stock valued at $160,329,000 after purchasing an additional 96,763 shares in the last quarter. State Street Corp increased its stake in Corcept Therapeutics by 0.5% in the fourth quarter. State Street Corp now owns 2,986,056 shares of the biotechnology company’s stock valued at $103,915,000 after purchasing an additional 15,656 shares in the last quarter. Geode Capital Management LLC raised its holdings in Corcept Therapeutics by 38.0% in the fourth quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock worth $92,892,000 after purchasing an additional 734,646 shares during the period. Finally, First Trust Advisors LP raised its holdings in Corcept Therapeutics by 213.5% in the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after purchasing an additional 1,480,059 shares during the period. 93.61% of the stock is owned by institutional investors.

Corcept Therapeutics Company Profile

(Get Free Report)

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.